Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy

Imagem de Miniatura
Arquivos
art_MEDRANO_Immunomodulatory_and_antitumor_effects_of_type_I_interferons_2017.PDF (13.53 MB)
Citações na Scopus
123
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IMPACT JOURNALS LLC
Autores
BARBUTO, Jose Alexandre M.
Citação
ONCOTARGET, v.8, n.41, p.71249-71284, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
During the last decades, the pleiotropic antitumor functions exerted by type I interferons (IFNs) have become universally acknowledged, especially their role in mediating interactions between the tumor and the immune system. Indeed, type I IFNs are now appreciated as a critical component of dendritic cell (DC) driven T cell responses to cancer. Here we focus on IFN-alpha and IFN-beta, and their antitumor effects, impact on immune responses and their use as therapeutic agents. IFN-alpha/beta share many properties, including activation of the JAK-STAT signaling pathway and induction of a variety of cellular phenotypes. For example, type I IFNs drive not only the high maturation status of DCs, but also have a direct impact in cytotoxic T lymphocytes, NK cell activation, induction of tumor cell death and inhibition of angiogenesis. A variety of stimuli, including some standard cancer treatments, promote the expression of endogenous IFN-alpha/beta, which then participates as a fundamental component of immunogenic cell death. Systemic treatment with recombinant protein has been used for the treatment of melanoma. The induction of endogenous IFN-alpha/beta has been tested, including stimulation through pattern recognition receptors. Gene therapies involving IFN-alpha/beta have also been described. Thus, harnessing type I IFNs as an effective tool for cancer therapy continues to be studied.
Palavras-chave
IFNAR1/2, JAK-STAT, apoptosis, necroptosis, immunogenic cell death
URI
https://observatorio.fm.usp.br/handle/OPI/22044
Referências
  1. Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
  2. Ablasser A, 2016, J MOL MED, V94, P1085, DOI 10.1007/s00109-016-1423-2
  3. Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306
  4. Adachi K, 2015, CANCER SCI, V106, P945, DOI 10.1111/cas.12695
  5. Aguiar RCT, 1997, LEUKEMIA, V11, P233, DOI 10.1038/sj.leu.2400553
  6. Ahn MY, 2012, J ORAL PATHOL MED, V41, P540, DOI 10.1111/j.1600-0714.2012.01158.x
  7. Aida K, 2014, CANCER SCI, V105, P159, DOI 10.1111/cas.12332
  8. Albini A, 2000, AM J PATHOL, V156, P1381, DOI 10.1016/S0002-9440(10)65007-9
  9. Alexopoulou L, 2012, M S-MED SCI, V28, P96, DOI 10.1051/medsci/2012281023
  10. Nocera DA, 2016, J IMMUNOL, V196, P2860, DOI 10.4049/jimmunol.1501044
  11. Aoyagi S, 2012, ONCOLOGY-BASEL, V82, P139, DOI 10.1159/000336490
  12. Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111
  13. Bajgelman MC, 2008, VIROLOGY, V371, P8, DOI 10.1016/j.virol.2007.11.015
  14. Ballas ZK, 1996, J IMMUNOL, V157, P1840
  15. Banday AH, 2015, IMMUNOPHARM IMMUNOT, V37, P1, DOI 10.3109/08923973.2014.971963
  16. Barber GN, 2011, IMMUNOL REV, V243, P99, DOI 10.1111/j.1600-065X.2011.01051.x
  17. Barnard P, 2000, VIROLOGY, V277, P411, DOI 10.1006/viro.2000.0584
  18. Baumgaertner P, 2012, INT J CANCER, V130, P2607, DOI 10.1002/ijc.26297
  19. Beglin M, 2009, J INTERF CYTOK RES, V29, P629, DOI 10.1089/jir.2009.0075
  20. Belardelli F, 2002, CYTOKINE GROWTH F R, V13, P119, DOI 10.1016/S1359-6101(01)00022-3
  21. Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022
  22. Benwell RK, 2010, CELL IMMUNOL, V264, P119, DOI 10.1016/j.cellimm.2010.05.008
  23. Berzofsky JA, 2004, J CLIN INVEST, V113, P1515, DOI 10.1172/JCI200-421926
  24. Beutner KR, 1999, J AM ACAD DERMATOL, V41, P1002, DOI 10.1016/S0190-9622(99)70261-6
  25. Borden EC, 2011, J INTERF CYTOK RES, V31, P433, DOI 10.1089/jir.2010.0054
  26. Bossi G, 2007, HEAD NECK-J SCI SPEC, V29, P272, DOI 10.1002/hed.20529
  27. BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655
  28. Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007
  29. Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820
  30. Cao GW, 2001, CANCER GENE THER, V8, P497, DOI 10.1038/sj.cgt.7700333
  31. Cao W, 2010, IMMUNOL REV, V234, P163, DOI 10.1111/j.0105-2896.2009.00867.x
  32. Cao W, 2009, J CLIN IMMUNOL, V29, P257, DOI 10.1007/s10875-009-9284-x
  33. Caporali A, 2008, CIRC RES, V103, pE15, DOI 10.1161/CIRCRESAHA.108.177386
  34. Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
  35. Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171
  36. Caspi RR, 2008, NAT REV IMMUNOL, V8, P970, DOI 10.1038/nri2438
  37. Catarinella M, 2016, EMBO MOL MED, V8, P155, DOI 10.15252/emmm.201505395
  38. Cella M, 1999, NAT MED, V5, P919
  39. Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821
  40. Cheever MAM, 2008, IMMUNOL REV, V222, P357, DOI 10.1111/j.1600-065X.2008.00604.x
  41. Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
  42. Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183
  43. Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268
  44. Chen ZH, 1996, CANCER RES, V56, P1083
  45. Cheng XW, 2012, J BIOL CHEM, V287, P23356, DOI 10.1074/jbc.M112.340505
  46. Cheng YS, 2010, CANCER BIOL THER, V10, P1219, DOI 10.4161/cbt.10.12.13450
  47. Chiang CLL, 2008, CLIN CANCER RES, V14, P4898, DOI 10.1158/1078-0432.CCR-07-4899
  48. Chiang CLL, 2013, CLIN CANCER RES, V19, P4801, DOI 10.1158/1078-0432.CCR-13-1185
  49. Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5
  50. Chiocca EA, 2008, MOL THER, V16, P618, DOI 10.1038/sj.mt.6300396
  51. Cho JH, 2017, ONCOTARGET, V8, P24932, DOI 10.18632/oncotarget.15326
  52. Ciampricotti M, 2012, NAT MED, V18, P344, DOI 10.1038/nm.2652
  53. COHEN B, 1995, MOL CELL BIOL, V15, P4208
  54. COLAMONICI OR, 1992, BLOOD, V80, P744
  55. COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518
  56. COLEMAN A, 1994, CANCER RES, V54, P344
  57. Crouse J, 2014, IMMUNITY, V40, P961, DOI 10.1016/j.immuni.2014.05.003
  58. Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038
  59. Da Silva DM, 2015, CLIN IMMUNOL, V161, P197, DOI 10.1016/j.clim.2015.09.003
  60. Daud A, 2012, EXPERT OPIN BIOL TH, V12, P1087, DOI 10.1517/14712598.2012.694421
  61. De Palma M, 2008, CANCER CELL, V14, P299, DOI 10.1016/j.ccr.2008.09.004
  62. Deininger S, 2003, J IMMUNOL, V170, P4134
  63. Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112
  64. Di Trolio R, 2015, CYTOKINE GROWTH F R, V26, P203, DOI 10.1016/j.cytogfr.2014.11.008
  65. Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158
  66. DIAZ MO, 1994, GENOMICS, V22, P540, DOI 10.1006/geno.1994.1427
  67. DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259
  68. Dickson PV, 2007, MOL CANCER RES, V5, P531, DOI 10.1158/1541-7786.MCR-06-0259
  69. Dietrich N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010250
  70. Dietz AB, 2001, GENE THER, V8, P419, DOI 10.1038/sj.gt.3301406
  71. Dinney CPN, 2013, J UROLOGY, V190, P850, DOI 10.1016/j.juro.2013.03.030
  72. Dinney CPN, 1998, CANCER RES, V58, P808
  73. DiPaola RS, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-20
  74. Dohnal AM, 2007, CYTOTHERAPY, V9, P755, DOI 10.1080/14653240701589221
  75. Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388
  76. Drobits B, 2012, J CLIN INVEST, V122, P575, DOI 10.1172/JCI61034
  77. Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961
  78. Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213
  79. Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010
  80. Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101
  81. DVORAK HF, 1989, J NATL CANCER I, V81, P497, DOI 10.1093/jnci/81.7.497
  82. Eggermont AMM, 2016, EUR J CANCER, V55, P111, DOI 10.1016/j.ejca.2015.11.014
  83. EINHORN S, 1990, CANCER RES, V50, P7781
  84. Engelhardt JJ, 2012, CANCER CELL, V21, P402, DOI 10.1016/j.ccr.2012.01.008
  85. Erdmann J, 2011, J INTERF CYTOK RES, V31, P451, DOI 10.1089/jir.2009.0103
  86. Fidler IJ, 2002, LANCET ONCOL, V3, P53, DOI 10.1016/S1470-2045(01)00622-2
  87. FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
  88. FOLKMAN J, 1990, J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
  89. Fondello C, 2016, BIOMED PHARMACOTHER, V83, P290, DOI 10.1016/j.biopha.2016.06.038
  90. FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557
  91. Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618
  92. Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
  93. Fruci D, 2012, CURR ONCOL, V19, P39, DOI 10.3747/co.19.945
  94. Gajewski TF, 2007, CLIN CANCER RES, V13, P5256, DOI 10.1158/1078-0432.CCR-07-0892
  95. Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
  96. Gajewski TF, 2012, CANCER IMMUNOL IMMUN, V61, P1343, DOI 10.1007/s00262-012-1305-6
  97. Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI [10.1038/nri.2016.107, 10.1038/nn.2016.107]
  98. Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626
  99. Gantier MP, 2008, J IMMUNOL, V180, P2117
  100. Gardner A, 2016, TRENDS IMMUNOL, V37, P855, DOI 10.1016/j.it.2016.09.006
  101. Garg AD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0105
  102. Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839
  103. Gavutis M, 2005, BIOPHYS J, V88, P4289, DOI 10.1529/biophysj.104.055855
  104. Gessani S, 2014, TOXINS, V6, P1696, DOI 10.3390/toxins6061696
  105. Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179
  106. Gogas H, 2015, AM J THER, V22, P54, DOI 10.1097/MJT.0b013e31829e883d
  107. Goldinger SM, 2012, EUR J IMMUNOL, V42, P3049, DOI 10.1002/eji.201142361
  108. Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872
  109. GRANDER D, 1992, BLOOD, V79, P2076
  110. GREINER JW, 1984, CANCER RES, V44, P3208
  111. GuhaSarkar D, 2017, MOL ONCOL, V11, P180, DOI 10.1002/1878-0261.12020
  112. GuhaSarkar D, 2016, NEURO-ONCOLOGY, V18, P1508, DOI 10.1093/neuonc/now097
  113. Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401
  114. Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712
  115. Guo XH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00158
  116. Hara H, 2007, CANCER SCI, V98, P455, DOI 10.1111/j.1349-7006.2007.00408.x
  117. Harden JL, 2012, IMMUNOL INVEST, V41, P738, DOI 10.3109/08820139.2012.676122
  118. Hartmann E, 2003, CANCER RES, V63, P6478
  119. Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305
  120. Hatanaka K, 2004, J GENE MED, V6, P1139, DOI 10.1002/jgm.602
  121. Heil M, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00578
  122. Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200
  123. Hellman P, 2007, HUM IMMUNOL, V68, P324, DOI 10.1016/j.humimm.2007.01.018
  124. Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
  125. Hemmi H, 2000, NATURE, V408, P740
  126. Hendren SK, 2004, SURGERY, V135, P427, DOI 10.1016/j.surg.2003.08.015
  127. Hesling C, 2004, BRIT J DERMATOL, V150, P761, DOI 10.1111/j.0007-0963.2004.05898.x
  128. HEYMAN M, 1994, LEUKEMIA, V8, P425
  129. HEYMAN M, 1993, INT J CANCER, V54, P748, DOI 10.1002/ijc.2910540507
  130. Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206
  131. Hochrein H, 2002, HUM IMMUNOL, V63, P1103, DOI 10.1016/S0198-8859(02)00748-6
  132. Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066
  133. Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009
  134. Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900
  135. Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
  136. Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj/onc/1205341
  137. Huang YK, 2013, TUMOR BIOL, V34, P1615, DOI 10.1007/s13277-013-0693-3
  138. Huber JP, 2011, IMMUNOLOGY, V132, P466, DOI 10.1111/j.1365-2567.2011.03412.x
  139. Hunger Aline, 2017, Cell Death Discov, V3, P17017, DOI 10.1038/cddiscovery.2017.17
  140. Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6
  141. Iannello Alexandre, 2013, Cold Spring Harb Symp Quant Biol, V78, P249, DOI 10.1101/sqb.2013.78.020255
  142. Indraccolo S, 2005, HUM GENE THER, V16, P957, DOI 10.1089/hum.2005.16.957
  143. ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048
  144. Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476
  145. Izawa JI, 2002, CLIN CANCER RES, V8, P1258
  146. Jablonska J, 2010, J CLIN INVEST, V120, P4163, DOI 10.1172/JCI37223
  147. Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006
  148. Jaks E, 2007, J MOL BIOL, V366, P525, DOI 10.1016/j.jmb.2006.11.053
  149. JAMES CD, 1993, CANCER RES, V53, P3674
  150. Janco JMT, 2015, J IMMUNOL, V194, P2985, DOI 10.4049/jimmunol.1403134
  151. Janmohamed SR, 2015, EUR J PEDIATR, V174, P259, DOI 10.1007/s00431-014-2404-5
  152. Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
  153. Kaehler KC, 2010, EUR J CANCER, V46, P41, DOI 10.1016/j.ejca.2009.10.004
  154. Kagan JC, 2014, COLD SPRING HARB PER, V7
  155. Kalb ML, 2012, J IMMUNOL, V188, P1583, DOI 10.4049/jimmunol.1102437
  156. Kalie E, 2008, J BIOL CHEM, V283, P32925, DOI 10.1074/jbc.M806019200
  157. Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292
  158. Katlinski KV, 2017, CANCER CELL, V31, P194, DOI 10.1016/j.ccell.2017.01.004
  159. Kauffman E. C., 2012, J ONCOL, V2012, DOI [DOI 10.1155/2012/103298, 10.1155/2012/103298]
  160. Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303
  161. Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
  162. Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
  163. Keirsse J, 2017, J LEUKOC BIOL
  164. Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691
  165. Kiladjian JJ, 2016, LEUKEMIA, V30, P776, DOI 10.1038/leu.2015.326
  166. KIM HR, 2016, SCI REP UK, V6
  167. Kirkwood JM, 1996, J CLIN ONCOL, V14, P7
  168. Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370
  169. Klarquist JS, 2012, ONCOIMMUNOLOGY, V1, P1584, DOI 10.4161/onci.22660
  170. Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2
  171. Koks CA, 2015, INT J CANCER, V136, pE313, DOI 10.1002/ijc.29202
  172. Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414
  173. Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
  174. Kruklitis RJ, 2004, J THORAC CARDIOV SUR, V127, P123, DOI 10.1016/j.jtcvs.2003.08.034
  175. Kumagai Y, 2008, ADV DRUG DELIVER REV, V60, P795, DOI 10.1016/j.addr.2007.12.004
  176. Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004
  177. Kurisetty VVS, 2014, HEAD NECK-J SCI SPEC, V36, P1619, DOI 10.1002/hed.23502
  178. Kuwashima N, 2005, J IMMUNOL, V175, P2730
  179. Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014
  180. Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0
  181. Le Mercier I, 2013, CANCER RES, V73, P4629, DOI 10.1158/0008-5472.CAN-12-3058
  182. Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860
  183. Lee MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074698
  184. Lee SK, 2014, CLIN CANCER RES, V20, P3485, DOI 10.1158/1078-0432.CCR-13-2522
  185. Lee SE, 2012, GASTROENTEROLOGY, V143, P145, DOI 10.1053/j.gastro.2012.03.042
  186. Lemos H, 2016, CANCER RES, V76, P2076, DOI 10.1158/0008-5472.CAN-15-1456
  187. LEVY DE, 1990, EMBO J, V9, P1105
  188. LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362
  189. LEVY HB, 1975, J INFECT DIS, V132, P434
  190. Li Vincent W, 2005, J Drugs Dermatol, V4, P708
  191. Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040
  192. Lienenklaus S, 2009, J IMMUNOL, V183, P3229, DOI 10.4049/jimmunol.0804277
  193. Lin SC, 2010, NATURE, V465, P885, DOI 10.1038/nature09121
  194. Lippens C, 2016, J AUTOIMMUN, V75, P39, DOI 10.1016/j.jaut.2016.07.004
  195. Lydiatt WM, 1998, HEAD NECK-J SCI SPEC, V20, P113, DOI 10.1002/(SICI)1097-0347(199803)20:2<113::AID-HED3>3.0.CO;2-5
  196. Lykhova AA, 2015, CYTOKINE, V71, P318, DOI 10.1016/j.cyto.2014.10.029
  197. Ma ZD, 2001, J IMMUNOL, V167, P5150
  198. Malek A, 2010, METHODS MOL BIOL, V623, P423, DOI 10.1007/978-1-60761-588-0_27
  199. Mancuso G, 2007, J IMMUNOL, V178, P3126
  200. Martinez-Pomares L, 2012, TRENDS IMMUNOL, V33, P66, DOI 10.1016/j.it.2011.11.001
  201. Matsumoto K, 2008, JPN J CLIN ONCOL, V38, P849, DOI 10.1093/jjco/hyn114
  202. McCartney S, 2009, J EXP MED, V206, P2967, DOI 10.1084/jem.20091181
  203. McCarty MF, 2002, CLIN EXP METASTAS, V19, P609, DOI 10.1023/A:1020923326441
  204. McMasters KM, 2016, J CLIN ONCOL, V34, P1079, DOI 10.1200/JCO.2015.63.3776
  205. McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787
  206. Merkel CA, 2013, CANCER GENE THER, V20, P317, DOI 10.1038/cgt.2013.23
  207. Meyer S, 2010, EXP DERMATOL, V19, pE251, DOI 10.1111/j.1600-0625.2010.01072.x
  208. Minutilli E, 2012, TUMORI, V98, P185, DOI 10.1700/1088.11928
  209. Mohr P, 2015, J CLIN ONCOL, V33, P4077, DOI 10.1200/JCO.2014.59.6932
  210. Moraga I, 2009, MOL CELL BIOL, V29, P4778, DOI 10.1128/MCB.01808-08
  211. Moschos S, 2007, CYTOKINE GROWTH F R, V18, P451, DOI 10.1016/j.cytogfr.2007.06.020
  212. Moschos SJ, 2006, J CLIN ONCOL, V24, P3164, DOI 10.1200/JCO.2005.05.2498
  213. Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073
  214. Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583
  215. Murata M, 2006, CYTOKINE, V33, P121, DOI 10.1016/j.cyto.2005.08.011
  216. Murphy D, 2001, HEPATOLOGY, V33, P346, DOI 10.1053/jhep.2001.21749
  217. Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204
  218. Muzio M, 2000, J IMMUNOL, V164, P5998
  219. Narumi K, 2010, CANCER SCI, V101, P1686, DOI 10.1111/j.1349-7006.2010.01578.x
  220. Navabi H, 2009, VACCINE, V27, P107, DOI 10.1016/j.vaccine.2008.10.024
  221. Nelissen I, 2002, J LEUKOCYTE BIOL, V71, P89
  222. NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993
  223. Noguchi T, 2017, CANCER IMMUNOL RES, V5, P106, DOI 10.1158/2326-6066.CIR-16-0391
  224. NOVICK D, 1987, J BIOL CHEM, V262, P8483
  225. O'Sullivan T, 2012, J EXP MED, V209, P1869, DOI 10.1084/jem.20112738
  226. Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
  227. Odaka M, 2001, CANCER RES, V61, P6201
  228. Odorizzi PM, 2013, SCIENCE, V340, P155, DOI 10.1126/science.1237568
  229. Ohashi M, 2005, BRIT J CANCER, V93, P441, DOI 10.1038/sj.bjc.6602713
  230. Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511
  231. Palamara F, 2004, J IMMUNOL, V173, P3051
  232. Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4
  233. Park JA, 2006, ONCOL REP, V16, P1253
  234. Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14
  235. Parlato S, 2001, BLOOD, V98, P3022, DOI 10.1182/blood.V98.10.3022
  236. Parlato S, 2010, BLOOD, V115, P1554, DOI 10.1182/blood-2009-07-234468
  237. Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
  238. Patel MR, 2015, ONCOTARGET, V6, P33165, DOI 10.18632/oncotarget.5320
  239. Perales-Linares R, 2013, IMMUNOLOGY, V140, P153, DOI 10.1111/imm.12143
  240. Perreau M, 2007, J VIROL, V81, P3272, DOI 10.1128/JVI.01530-06
  241. Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x
  242. Pestka S., 1997, SEMIN ONCOL, V24
  243. Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024
  244. Piehler J, 2012, IMMUNOL REV, V250, P317, DOI 10.1111/imr.12001
  245. Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
  246. Platanias LC, 1996, J BIOL CHEM, V271, P23630
  247. Ponsaerts P, 2002, LEUKEMIA, V16, P1324, DOI 10.1038/sj.leu.2402511
  248. Catani JPP, 2016, TRANSL ONCOL, V9, P565, DOI 10.1016/j.tranon.2016.09.011
  249. Prendergast GC, 2014, CANCER IMMUNOL IMMUN, V63, P721, DOI 10.1007/s00262-014-1549-4
  250. Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563
  251. Puccetti P, 2007, EUR J IMMUNOL, V37, P876, DOI 10.1002/eji.200737184
  252. Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038
  253. Regnier-Rosencher E, 2013, J AM ACAD DERMATOL, V68, P313, DOI 10.1016/j.jaad.2012.04.018
  254. Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362
  255. Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101
  256. Reznikov LL, 1998, J INTERF CYTOK RES, V18, P897, DOI 10.1089/jir.1998.18.897
  257. Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563
  258. Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003
  259. Roh MR, 2013, MELANOMA RES, V23, P114, DOI 10.1097/CMR.0b013e32835e7713
  260. Rolf N, 2015, EUR J IMMUNOL, V45, P1980, DOI 10.1002/eji.201444874
  261. Romero-Weaver AL, 2010, MOL CANCER RES, V8, P80, DOI 10.1158/1541-7786.MCR-08-0344
  262. Rosewicz Stefan, 2004, Neuroendocrinology, V80 Suppl 1, P85, DOI 10.1159/000080748
  263. Rossi UA, 2017, CYTOKINE, V89, P201, DOI 10.1016/j.cyto.2015.11.012
  264. Rossi UA, 2015, BIOMED PHARMACOTHER, V72, P44, DOI 10.1016/j.biopha.2015.04.002
  265. Rozera C, 1999, AM J PATHOL, V154, P1211, DOI 10.1016/S0002-9440(10)65373-4
  266. Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215
  267. Saadeh D, 2016, J DERMATOL SCI, V83, P3, DOI 10.1016/j.jdermsci.2016.05.008
  268. Sabbatini P, 2012, CLIN CANCER RES, V18, P6497, DOI 10.1158/1078-0432.CCR-12-2189
  269. Salem ML, 2009, VACCINE, V27, P549, DOI 10.1016/j.vaccine.2008.11.013
  270. Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012
  271. Saloura V, 2010, HUM GENE THER, V21, P51, DOI 10.1089/hum.2009.088
  272. Sandoval R, 2004, J BIOL CHEM, V279, P32275, DOI 10.1074/jbc.M313830200
  273. Sato Yusuke, 2009, Cancer Microenviron, V2 Suppl 1, P205, DOI 10.1007/s12307-009-0022-y
  274. Schiavoni G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00483
  275. SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401
  276. Schmidt-Wolf IGH, 2002, BRIT J HAEMATOL, V117, P23
  277. Schoggins JW, 2015, NATURE, V525, P144, DOI [10.1038/nature14554, 10.1038/nature14555, 10.1038/nature12862]
  278. Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
  279. Schuster IS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00235
  280. Segura E, 2013, TRENDS IMMUNOL, V34, P440, DOI 10.1016/j.it.2013.06.001
  281. Serra-Guillen C, 2012, J AM ACAD DERMATOL, V66, pE131, DOI 10.1016/j.jaad.2011.11.933
  282. SHAABANI N, 2016, CELL DEATH DIS, V7
  283. Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461
  284. Shih CS, 2009, NEUROMOL MED, V11, P43, DOI 10.1007/s12017-009-8059-0
  285. Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996
  286. SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3
  287. SIDKY YA, 1987, CANCER RES, V47, P5155
  288. Sin WX, 2012, IMMUNOL RES, V53, P25, DOI 10.1007/s12026-012-8293-7
  289. Singh RK, 1996, J INTERF CYTOK RES, V16, P577, DOI 10.1089/jir.1996.16.577
  290. SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562
  291. Sisirak V, 2012, CANCER RES, V72, P5188, DOI 10.1158/0008-5472.CAN-11-3468
  292. Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
  293. Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011
  294. Sluijter BJR, 2015, CANCER IMMUNOL RES, V3, P495, DOI 10.1158/2326-6066.CIR-14-0165
  295. Smits ELJM, 2009, HUM GENE THER, V20, P1106, DOI 10.1089/hum.2009.145
  296. Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005
  297. Sozzani S, 2010, TRENDS IMMUNOL, V31, P270, DOI 10.1016/j.it.2010.05.004
  298. Spaapen RM, 2014, J IMMUNOL, V193, P4254, DOI 10.4049/jimmunol.1401109
  299. Stack J, 2014, J IMMUNOL, V193, P6090, DOI 10.4049/jimmunol.1401605
  300. Stadler M, 1995, ONCOGENE, V11, P2565
  301. Stark GR, 2007, CYTOKINE GROWTH F R, V18, P419, DOI 10.1016/j.cytogfr.2007.06.013
  302. Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
  303. STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142
  304. STEINMAN RM, 1979, J EXP MED, V149, P1, DOI 10.1084/jem.149.1.1
  305. Sterman DH, 2006, NAT CLIN PRACT ONCOL, V3, P633, DOI 10.1038/ncponc0658
  306. Sterman DH, 2010, MOL THER, V18, P852, DOI 10.1038/mt.2009.309
  307. Strauss BE, 2013, RECENT ADV BIOL THER
  308. Streck CJ, 2005, CLIN CANCER RES, V11, P6020, DOI 10.1158/1078-0432.CCR-05-0502
  309. Sugawa N, 1993, Noshuyo Byori, V10, P161
  310. Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
  311. Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
  312. Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850
  313. Tan YH, 2015, IMMUNITY, V43, P909, DOI 10.1016/j.immuni.2015.10.008
  314. Tarhini AA, 2014, HEMATOL ONCOL CLIN N, V28, P471, DOI 10.1016/j.hoc.2014.02.004
  315. Taylor KL, 2008, J INTERF CYTOK RES, V28, P733, DOI 10.1089/jir.2008.0030
  316. Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214
  317. TERRIS B, 1995, CANCER RES, V55, P1590
  318. Thomann S, 2015, IMMUNOLOGY, V146, P327, DOI 10.1111/imm.12509
  319. Thompson KA, 1996, EUR J CLIN MICROBIOL, V15, P580, DOI 10.1007/BF01709367
  320. Timares Laura, 2004, Methods Mol Biol, V246, P139
  321. Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774
  322. Tsugawa T, 2004, GENE THER, V11, P1551, DOI 10.1038/sj.gt.3302300
  323. Ueda Y, 2007, CANCER IMMUNOL IMMUN, V56, P381, DOI 10.1007/s00262-006-0197-8
  324. Urosevic M, 2005, J NATL CANCER I, V97, P1143, DOI 10.1093/jnci/dji207
  325. Uze G, 2007, CURR TOP MICROBIOL, V316, P71
  326. van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014
  327. van Egmond S, 2007, INT J DERMATOL, V46, P318, DOI 10.1111/j.1365-4632.2007.03200.x
  328. van Poelgeest MIE, 2005, CLIN CANCER RES, V11, P5273, DOI 10.1158/1078-0432.CCR-05-0616
  329. Veglia F, 2017, CURR OPIN IMMUNOL, V45, P43, DOI 10.1016/j.coi.2017.01.002
  330. Vermi W, 2011, J LEUKOCYTE BIOL, V90, P681, DOI 10.1189/jlb.0411190
  331. Medrano RFV, 2016, CANCER IMMUNOL IMMUN, V65, P371, DOI 10.1007/s00262-016-1807-8
  332. Villaverde MS, 2012, CANCER GENE THER, V19, P508, DOI 10.1038/cgt.2012.27
  333. Viscomi GC, 1997, BIOTHERAPY, V10, P59, DOI 10.1007/BF02678218
  334. Voelter-Mahlknecht Susanne, 2006, Skinmed, V5, P271, DOI 10.1111/j.1540-9740.2006.05678.x
  335. von Marschall Z, 2003, J NATL CANCER I, V95, P437
  336. Wagner TC, 2004, INT J CANCER, V111, P32, DOI 10.1002/ijc.20236
  337. Wakabayashi T, 2008, J GENE MED, V10, P329, DOI 10.1002/jgm.1160
  338. Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114
  339. Wang XH, 2017, CANCER RES, V77, P839, DOI 10.1158/0008-5472.CAN-15-3142
  340. Wang YM, 2012, CELL HOST MICROBE, V11, P631, DOI 10.1016/j.chom.2012.05.003
  341. Weise AM, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-014-0409-x
  342. Whitty A, 1998, P NATL ACAD SCI USA, V95, P13165, DOI 10.1073/pnas.95.22.13165
  343. Wilderman MJ, 2005, CANCER RES, V65, P8379, DOI 10.1158/0008-5472.CAN-05-0920
  344. Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208
  345. Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017
  346. Wood A, 1997, BRIT J HAEMATOL, V98, P1002, DOI 10.1046/j.1365-2141.1997.2903110.x
  347. Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
  348. Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404
  349. Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029
  350. Yang H, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1149673
  351. Yang I, 2004, J NEUROSURG, V100, P310, DOI 10.3171/jns.2004.100.2.0310
  352. Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624
  353. Yano H, 2006, LIVER INT, V26, P964, DOI 10.1111/j.1478-3231.2006.01321.x
  354. Yi JY, 2009, BIOCHEM BIOPH RES CO, V386, P455, DOI 10.1016/j.bbrc.2009.06.046
  355. Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970
  356. Yonemitsu Y, 2008, FRONT BIOSCI-LANDMRK, V13, P1892, DOI 10.2741/2809
  357. Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095
  358. Zelenay S, 2012, J CLIN INVEST, V122, P1615, DOI 10.1172/JCI60644
  359. Zhang HY, 1996, CANCER GENET CYTOGEN, V86, P22, DOI 10.1016/0165-4608(95)00157-3
  360. Zhang Y, 2011, J IMMUNOL, V186, P1963, DOI 10.4049/jimmunol.1002320
  361. Zhang YF, 2014, CLIN IMMUNOL, V154, P26, DOI 10.1016/j.clim.2014.06.004
  362. Zheng H, 2011, BLOOD, V118, P4003, DOI 10.1182/blood-2011-06-359745
  363. Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03